MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
Open Access
- 22 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 3 (3), e105
- https://doi.org/10.1038/bcj.2013.1
Abstract
The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.Keywords
This publication has 97 references indexed in Scilit:
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer, 2010
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoBritish Journal of Haematology, 2010
- The use of novel agents in the treatment of relapsed and refractory multiple myelomaLeukemia, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Bone marrow microenvironment and the identification of new targets for myeloma therapyLeukemia, 2008
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionNature Structural & Molecular Biology, 2004
- Mutations of the BRAF gene in human cancerNature, 2002